Quantbot Technologies LP purchased a new position in LivaNova PLC (NASDAQ:LIVN) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 11,999 shares of the company’s stock, valued at approximately $1,487,000.
Other hedge funds also recently added to or reduced their stakes in the company. Harvest Fund Management Co. Ltd purchased a new position in LivaNova in the 3rd quarter worth approximately $108,000. grace capital purchased a new position in LivaNova in the 2nd quarter worth approximately $100,000. Gilder Gagnon Howe & Co. LLC purchased a new position in LivaNova in the 3rd quarter worth approximately $167,000. Cerebellum GP LLC purchased a new position in LivaNova in the 3rd quarter worth approximately $191,000. Finally, Envestnet Asset Management Inc. grew its stake in LivaNova by 1,054.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock worth $166,000 after buying an additional 1,518 shares in the last quarter. 82.26% of the stock is owned by institutional investors and hedge funds.
A number of equities analysts have commented on LIVN shares. ValuEngine cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Stifel Nicolaus boosted their price target on shares of LivaNova from $135.00 to $140.00 and gave the stock a “buy” rating in a research note on Monday, September 17th. BidaskClub cut shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 18th. Jefferies Financial Group boosted their price target on shares of LivaNova to $150.00 and gave the stock a “buy” rating in a research note on Tuesday, October 2nd. Finally, UBS Group started coverage on shares of LivaNova in a research note on Tuesday, November 27th. They issued a “neutral” rating and a $105.00 price objective for the company. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. LivaNova currently has an average rating of “Buy” and an average target price of $122.20.
LivaNova (NASDAQ:LIVN) last announced its quarterly earnings data on Wednesday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The business had revenue of $272.10 million during the quarter, compared to analysts’ expectations of $275.03 million. During the same period last year, the company posted $0.83 EPS. LivaNova’s revenue for the quarter was up 8.3% on a year-over-year basis. As a group, equities research analysts forecast that LivaNova PLC will post 3.1 EPS for the current year.
In other news, insider David S. Wise sold 1,500 shares of the company’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $112.83, for a total value of $169,245.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Jeffrey Moore sold 1,000 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $123.49, for a total transaction of $123,490.00. The disclosure for this sale can be found here. Insiders sold a total of 8,500 shares of company stock valued at $1,002,355 in the last ninety days. 0.41% of the stock is owned by corporate insiders.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Recommended Story: Bear Market – How and Why They Occur
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.